Team: University of Calgary, Canada
Journal: Immunity (U.S.)
Type I diabetes is an autoimmune disease. Cytotoxic T lymphocytes attack the beta cells in the pancreas that produce insulin, recognizing a surface antigen of these cells. (Si quelqu'un connait le nom du peptide, je prends!).
The vaccine developed and tested on mice is made up of nanoparticles that have the peptide in question. This has the effect of stimulating T reg cells, suppressor, whose function is to inhibit the cytotoxic response responsible for diabetes.
trials on humans could begin within two years, but may not be as successful because of the large differences between systems immune human and mouse.
This remains a great news, because in addition to being a real bastard, diabetes (I and II) is the source of 12.5 billion euros (2.5 billion for Sanofi insulin) of annual expenditure for safety, with 5 billion more for indirect costs.
0 comments:
Post a Comment